Ivabradine: A Potential Therapeutic for Children With Refractory SVT
Nour K Younis1, Bernard Abi-Saleh1,2, Farah Al Amin3
1Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Insights
Ivabradine shows promise for treating refractory supraventricular tachycardia (SVT) in pediatric patients, demonstrating safety and efficacy in restoring normal heart rhythm. This off-label use warrants further investigation for pediatric SVT management.
Area of Science:
- Pediatric Cardiology
- Electrophysiology
- Pharmacology
Background:
- Ivabradine, FDA-approved for coronary artery disease and heart failure, has shown benefits in adult HF patients with elevated heart rates.
- Limited data exists on ivabradine's use in pediatric patients with supraventricular tachycardia (SVT), with current evidence primarily from case reports.
- Understanding ivabradine's role in refractory pediatric SVT is crucial for expanding treatment options.
Purpose of the Study:
- To evaluate the off-label use of ivabradine in pediatric patients diagnosed with supraventricular tachycardia (SVT).
- To assess the efficacy of ivabradine in managing treatment-resistant (refractory) pediatric SVT.
- To compare clinical outcomes of pediatric SVT patients treated with ivabradine to existing literature.
Main Methods:
- A retrospective, single-center observational study was conducted from January 2016 to October 2020.
- Pediatric patients with SVT were identified, with a specific focus on those with refractory SVT treated with ivabradine.
- Literature review of PubMed, Medline, and Google Scholar was performed to contextualize findings.
Main Results:
- Out of 79 pediatric SVT patients, only three (4%) presented with refractory SVT requiring ivabradine.
- Ivabradine, as monotherapy or in combination, achieved successful sinus rhythm in two of three patients (66%).
- Conventional anti-arrhythmics successfully treated the majority (96%) of pediatric SVT cases.
Conclusions:
- Ivabradine demonstrates promising efficacy and safety as an off-label treatment for refractory pediatric SVT.
- The medication facilitated SVT suppression, sinus rhythm restoration, and improved left ventricular function in the studied cohort.
- Further research is warranted to establish ivabradine's role in managing pediatric SVT.
Abstract:
Background: In April 2015, ivabradine was approved by the Food and Drug Administration for the treatment of patients with coronary artery disease and heart failure (HF). The use of this medication has been linked with improved clinical outcomes and reduced rates of hospitalization in patients with symptomatic HF and a baseline heart rate of 70 bpm and above. Nonetheless, little is known about the use of ivabradine in pediatric patients with supraventricular tachycardia (SVT). This use is not well-studied and is only endorsed by a few case reports and case series. Aim: This study discusses the off-label utilization of ivabradine in pediatric patients with SVT, and highlights its efficacy in treating treatment-resistant (refractory) SVT. Methods: We conducted a retrospective single-center observational study involving pediatric patients with SVT treated at our center between January 2016 and October 2020. We identified the total number of patients with SVT, and the number of patients with refractory SVT treated with Ivabradine. Similarly, we performed a thorough review of the databases of PubMed, Medline and Google Scholar to compare the clinical course of our patients to those described in the literature. Results: Between January 2016 and October 2020, 79 pediatric patients with SVT were seen and treated at our center. A treatment-resistant SVT was noted only in three patients (4%). Ivabradine was used in these patients as a single or combined therapy. The rest (96%) were successfully treated with conventional anti-arrhythmics such as β-blockers, flecainide, and other approved medications. In the ivabradine group, successful reversal to sinus rhythm was achieved in two of the three patients (66%), one patient was treated with a combination therapy of amiodarone and ivabradine, and the other patient was treated only with ivabradine. Conclusion: Overall, promissory results are associated with the use of ivabradine in pediatric patients with refractory SVT. Ivabradine appears to be a safe and well-tolerated medication that can induce adequate suppression of SVT, complete reversal to sinus rhythm, and effective enhancement of left ventricular function.
Related Concept Videos
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias